Biomarkers for cardiovascular–kidney metabolic syndrome: Clinical utility in diagnosis, screening, and treatment

Documenti analoghi

• Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial
  di: Ayodele Odutayo, et al.
  Pubblicazione: (2024)
• Effects of sotagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease stages 3 and 4
  di: Vikas S. Sridhar, et al.
  Pubblicazione: (2024)
• Inter‐relationships between cardiovascular, renal and metabolic diseases: Underlying evidence and implications for integrated interdisciplinary care and management
  di: Jiten Vora, et al.
  Pubblicazione: (2024)
• Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double‐blind, randomised, placebo‐controlled cross‐over trial
  di: Luxcia Kugathasan, et al.
  Pubblicazione: (2026)
• Explainable machine learning‐driven predictive modelling of incident cognitive impairment in individuals with early‐stage cardiovascular–kidney–metabolic syndrome: Insights from a longitudinal CHARLS cohort study
  di: Shoupeng Duan, et al.
  Pubblicazione: (2025)